Dabigatran vs Rivaroxaban for Nonvalvular Atrial Fibrillation
This cohort study compares risks of thromboembolic stroke, intracranial hemorrhage, major extracranial bleeding, and mortality in Medicare beneficiaries with nonvalvular atrial fibrillation who initiated dabigatran or rivaroxaban therapy for stroke prevention.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research
More News: Atrial Fibrillation | Bleeding | Hemorrhagic Stroke | Internal Medicine | Medicare | Pradaxa | Stroke | Study